Patients with K-ras wild-type tumours but harbouring BRAF mutations did not show any responses to cetuximab/panitumumab and had inferior survival compared to those without BRAF mutations (Di Nicolantonio et al, 2008; Cappuzzo et al, 2008b). Here, KRAS is linked to neoplasm.